Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Open Access Highly Accessed Research

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

Peter E Morris1*, Brian Zeno2, Andrew C Bernard3, Xiangning Huang4, Shampa Das4, Timi Edeki5, Steven G Simonson6 and Gordon R Bernard7

Author Affiliations

1 Wake Forest University School of Medicine, Winston Salem, NC, USA

2 Riverside Methodist Hospital, Columbus, OH, USA

3 University of Kentucky, Lexington, KY, USA

4 AstraZeneca, Alderley Park, Macclesfield, UK

5 AstraZeneca, Wilmington, DE, USA

6 Agennix Incorporated, Princeton, NJ, USA

7 Vanderbilt University, Nashville, TN, USA

For all author emails, please log on.

Critical Care 2012, 16:R31  doi:10.1186/cc11203

Published: 17 February 2012

Abstract

Introduction

Tumor necrosis factor-alpha (TNF-α), an early mediator in the systemic inflammatory response to infection, is a potential therapeutic target in sepsis. The primary objective of this study was to determine the safety and tolerability of AZD9773, an ovine, polyclonal, anti-human TNF-α Fab preparation, in patients with severe sepsis. Secondary outcomes related to pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

Methods

In this double-blind, placebo-controlled, multicenter Phase IIa study, patients were sequentially enrolled into five escalating-dose cohorts (single doses of 50 or 250 units/kg; multiple doses of 250 units/kg loading and 50 units/kg maintenance, 500 units/kg loading and 100 units/kg maintenance, or 750 units/kg loading and 250 units/kg maintenance). In each cohort, patients were randomized 2:1 to receive AZD9773 or placebo.

Results

Seventy patients received AZD9773 (n = 47) or placebo (n = 23). Baseline characteristics were similar across cohorts. Mean baseline APACHE score was 25.9. PK data demonstrated an approximately proportional increase in concentration with increasing dose and a terminal half-life of 20 hours. For the multiple-dose cohorts, serum TNF-α concentrations decreased to near-undetectable levels within two hours of commencing AZD9773 infusion. This suppression was maintained in most patients for the duration of treatment. AZD9773 was well tolerated. Most adverse events were of mild-to-moderate intensity and considered by the reporting investigator as unrelated to study treatment.

Conclusions

The safety, PK and PD data support the continued evaluation of AZD9773 in larger Phase IIb/III studies.